377 related articles for article (PubMed ID: 2932108)
1. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
[TBL] [Abstract][Full Text] [Related]
2. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D; Schmidt H
Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Rouse W; Riegler F
Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D
Cancer Res; 1983 Aug; 43(8):3696-9. PubMed ID: 6861140
[TBL] [Abstract][Full Text] [Related]
5. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin.
Chandrasekaran B; Dimling J; Capizzi RL
Cancer Treat Rep; 1987 Feb; 71(2):195-6. PubMed ID: 2948640
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
Hait WN; Pierson NR
Cancer Res; 1990 Feb; 50(4):1165-9. PubMed ID: 2297765
[TBL] [Abstract][Full Text] [Related]
7. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone.
Kamath N; Grabowski D; Ford J; Kerrigan D; Pommier Y; Ganapathi R
Biochem Pharmacol; 1992 Sep; 44(5):937-45. PubMed ID: 1356339
[TBL] [Abstract][Full Text] [Related]
9. P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype.
Badiner GJ; Moy BC; Smith KS; Tarpley WG; Groppi VE; Bhuyan BK
Br J Cancer; 1990 Sep; 62(3):378-84. PubMed ID: 2145026
[TBL] [Abstract][Full Text] [Related]
10. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei.
Capranico G; Riva A; Tinelli S; Dasdia T; Zunino F
Cancer Res; 1987 Jul; 47(14):3752-6. PubMed ID: 3474061
[TBL] [Abstract][Full Text] [Related]
11. Correlation between potency of calmodulin inhibitors and effects on cellular levels and cytotoxic activity of doxorubicin (adriamycin) in resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Turinic R; Valenzuela R
Eur J Cancer Clin Oncol; 1984 Jun; 20(6):799-806. PubMed ID: 6540180
[TBL] [Abstract][Full Text] [Related]
12. Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells.
Ganapathi R; Yen A; Grabowski D; Schmidt H; Turinic R; Valenzuela R
Br J Cancer; 1986 Apr; 53(4):561-6. PubMed ID: 3707847
[No Abstract] [Full Text] [Related]
13. Modulation of adriamycin and N-trifluoroacetyladriamycin-14-valerate induced effects on cell cycle traverse and cytotoxicity in P388 mouse leukemia cells by caffeine and the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D; Schmidt H; Yen A; Iliakis G
Cancer Res; 1986 Nov; 46(11):5553-7. PubMed ID: 3756902
[TBL] [Abstract][Full Text] [Related]
14. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)].
Sugimoto Y; Matsuo K; Takeda S; Yamada Y; Tsukagoshi S
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):353-8. PubMed ID: 2138003
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity to anthracyclines in P388/dx leukaemia cells.
Bossa R; Dasdia T; Galatulas I; Zunino F
Anticancer Res; 1986; 6(5):1037-9. PubMed ID: 3099628
[TBL] [Abstract][Full Text] [Related]
16. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
Young CW; Raymond V
Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
[No Abstract] [Full Text] [Related]
17. Flow cytometric monitoring of cellular anthracycline accumulation in murine leukemic cells.
Krishan A; Sauerteig A; Gordon K; Swinkin C
Cancer Res; 1986 Apr; 46(4 Pt 1):1768-73. PubMed ID: 3948163
[TBL] [Abstract][Full Text] [Related]
18. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.
McGovren JP
Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline-induced DNA breaks and resealing in doxorubicin-resistant murine leukemic P388 cells.
Maniar N; Krishan A; Israel M; Samy TS
Biochem Pharmacol; 1988 May; 37(9):1763-72. PubMed ID: 2837239
[TBL] [Abstract][Full Text] [Related]
20. Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide.
Johnson RK; Howard WS
Eur J Cancer Clin Oncol; 1982 May; 18(5):479-87. PubMed ID: 6956514
[No Abstract] [Full Text] [Related]
[Next] [New Search]
